NEW THERAPEUTIC STRATEGIES IN PATIENTS WITH METABOLIC SYNDROME AND HEART FAILURE
Abstract:
The aim of the study was to investigate the effects of 16-32 mg Candesartan Cilexil (Atacand ) in patients with heart failure and metabolic syndrome.
A prospective study with a follow up of 6 months was conducted. Thirty patients with metabolic syndrome and chronic heart failure from The Diagnostic and Treatment Centre, Cluj-Napoca were included into the study.
The homodynamic parameters expressed by ejection fraction, effort tolerance, and clinical symptomathology were improved in the patients treated with Atacand .This treatment efficiently controlled the 24 hour blood pressure, offering an increased cardiovascular protection with no effect on lipid and glucose metabolism.
full text article in English (.EN) |